FLT3 and melanoma: A phase II trial (NCT02129075) showed that poly-ICLC and fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhanced responses to dendritic cell (DC)-targeting vaccines in melanoma patients (131).